| MRP | : |
|
| Price | : | ₹3,000.00 |
| You Save | : | ₹281.25 (8.57%) |
1 vial(s) of 0.5ml
Mounjaro 2.5mg Injection is a cutting-edge injectable medication that contains Tirzepatide as its active ingredient. Classified under the pharmacological group of GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptor agonists, it is primarily utilized in the treatment of type 2 diabetes mellitus in adults. This medication is specifically designed to support blood glucose regulation, especially in individuals who struggle to achieve adequate control through oral antidiabetic medications alone.
Mounjaro works by mimicking the natural incretin hormones found in the body. It enhances insulin secretion in response to food intake and simultaneously suppresses glucagon secretion, a hormone that typically raises blood sugar levels. This dual action helps effectively reduce post-meal glucose spikes and improve overall glycemic control.
In addition to its role in managing diabetes, Mounjaro 2.5mg Injection has shown significant potential in supporting weight loss, making it a promising option for patients who are obese or those looking to enhance their metabolic health. As a result, it is commonly prescribed alongside dietary modifications and regular physical activity to optimize its therapeutic benefits.
However, the use of this medicine is not recommended for individuals with a personal or family history of medullary thyroid carcinoma or those diagnosed with multiple endocrine neoplasia syndrome type 2 (MEN 2). Patients with underlying kidney impairment, gastrointestinal disorders, or a history of pancreatitis should use this drug with caution.
Before initiating treatment with Mounjaro, healthcare professionals must assess the patient’s overall medical profile and potential risk factors. It is essential to closely monitor for any signs of thyroid tumors, inflammation of the pancreas (pancreatitis), and the occurrence of severe hypoglycemia, particularly when Mounjaro is used in combination with insulin or other blood sugar-lowering agents
FDA-approved uses of Mounjaro 2.5mg Injection include:
Mounjaro 2.5mg Injection functions by replicating the biological activity of two essential incretin hormones—GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). These naturally occurring hormones are central to maintaining proper blood glucose levels and coordinating the body's metabolic response following food consumption.
The mechanism of action involves several key processes:
Stimulating insulin secretion from the pancreas in response to food intake, which helps lower blood sugar levels more effectively.
Suppressing the release of glucagon, a hormone produced by the liver that typically increases blood glucose levels, thereby reducing unnecessary glucose production.
Delaying gastric emptying, which slows the movement of food from the stomach to the intestines. This leads to a prolonged sensation of fullness, decreasing appetite and potentially reducing overall calorie intake.
Through this dual hormone receptor agonism, Mounjaro not only helps regulate postprandial (after-meal) and fasting blood sugar levels but also promotes sustainable weight loss over time. This makes it a particularly beneficial treatment for individuals managing both type 2 diabetes and obesity-related metabolic concerns
When using Mounjaro 2.5mg Injection, it is crucial to be aware of potential interactions with other medications, as they may result in adverse or undesired effects. Always consult your healthcare provider before starting or combining treatments. Special attention should be given in the following situations:
Insulin or Sulfonylureas:
The concurrent use of Mounjaro with insulin or sulfonylurea-class drugs can significantly increase the risk of severe hypoglycemia (low blood sugar levels). Your physician may need to adjust the dose of these medications and closely monitor your blood glucose to ensure safety.
Oral Contraceptives:
Mounjaro may slow down the rate at which the stomach empties its contents (gastric emptying), potentially interfering with the absorption of oral contraceptives. This can reduce their effectiveness. Women of childbearing potential are advised to discuss alternative or additional non-hormonal birth control methods with their healthcare provider.
Warfarin:
This blood-thinning medication may have altered anticoagulant activity when used alongside Mounjaro. Regular monitoring of INR (International Normalized Ratio) and coagulation parameters is recommended to ensure therapeutic stability and reduce bleeding risks.
Digoxin:
The absorption of digoxin, a commonly prescribed medication for heart conditions, may be affected due to changes in gastrointestinal motility caused by Mounjaro. This could lead to variability in its therapeutic effect, necessitating dose monitoring and possible adjustments.
Medullary Thyroid Carcinoma (MTC):
Mounjaro should not be used in patients who have a personal or family history of medullary thyroid carcinoma, as it may pose a heightened risk of thyroid tumors.
Multiple Endocrine Neoplasia Syndrome Type 2 (MEN 2):
This injection is contraindicated in individuals diagnosed with MEN 2, a genetic condition associated with endocrine tumors, due to the increased risk of serious complications.
Severe Gastrointestinal Diseases:
Patients with a history of severe gastrointestinal disorders, including gastroparesis or chronic pancreatitis, should avoid this medication. It may exacerbate these conditions and lead to further complications.
Before initiating treatment with Mounjaro 2.5mg Injection, make sure to disclose all medications, supplements, herbal products, and over-the-counter drugs you are currently taking or have recently used. This enables your healthcare provider to prevent harmful drug interactions and adjust your treatment plan accordingly for maximum safety and effectiveness
Mounjaro 2.5mg Injection is formulated for subcutaneous use only, meaning it is injected beneath the skin rather than into a muscle or vein. This medication is designed to be administered once per week, and it can be given at any time of the day, with no requirement to coordinate with meal times.
The typical treatment begins with a starting dose of 2.5 mg, administered once weekly. This initial dosage helps the body adjust to the medication and allows healthcare providers to assess tolerance and effectiveness.
After a minimum of four weeks on the 2.5 mg dose, if the patient responds well and experiences minimal or manageable side effects, the dosage may be increased to 5 mg weekly.
If further improvement in glycemic control is needed, and the patient continues to tolerate the drug, the dose can be gradually titrated up to a maximum of 15 mg per week, based on clinical response and individual treatment goals.
Mounjaro should be injected subcutaneously into one of the following areas:
The abdomen (avoiding a 2-inch radius around the navel),
The front of the thighs, or
The back of the upper arms.
It is essential to rotate the injection site with each weekly dose to prevent skin irritation, swelling, or localized tissue damage. Injections should not be given into areas where the skin is tender, bruised, red, or hardened.
If a dose is missed, patients should administer it as soon as they remember, provided it is within 4 days (96 hours) of the missed dose.
If more than 4 days have passed, the missed dose should be skipped, and the patient should resume the medication on their next regularly scheduled injection day. Under no circumstances should two doses be taken within a short period to "make up" for the missed one.
Patients must strictly follow the dosing instructions provided by their healthcare provider. Any changes to the dosage—whether increases or decreases—should only be made under medical supervision.
If a patient experiences side effects, fluctuating blood sugar levels, or has concerns about injection technique or site reactions, they should immediately consult their doctor for guidance.
Close monitoring and open communication with the healthcare provider will help ensure the treatment remains both safe and effective throughout the course of therapy
Common Side Effects:
Serious Side Effects:
It is unknown whether Mounjaro 2.5mg Injection passes into breast milk. Breastfeeding mothers should seek medical advice.
Consuming alcohol may increase the risk of hypoglycemia. Limit alcohol intake while using this medication.
Use with caution in patients with liver impairment. Regular monitoring of liver enzymes is advisable.
No significant respiratory effects have been reported. Safe for individuals without lung complications.
Dizziness or hypoglycemia may affect alertness. Exercise caution when operating machinery.
Animal studies indicate potential harm to the fetus. Use during pregnancy only if clearly necessary.
Molecule Name: Tirzepatide
Therapeutic Class: Antidiabetic and weight management agent
Pharmacological Class: GLP-1 and GIP receptor agonists
Indications:
1. Type 2 diabetes mellitus
2. Weight management in adults with obesity
At Medfast, we’re dedicated to bringing you accurate, trustworthy, and expert-vetted health information. Our primary goal is to ensure you receive content that you can rely on.
It’s crucial to understand that everything on this website is for general information purposes only. This content is not a substitute for professional medical advice, diagnosis, or treatment. We can’t stress enough the importance of consulting with your own doctor. They are the only ones who can provide tailored advice for your specific health concerns or medication questions.
Please, never ignore or delay seeking professional medical advice because of something you’ve read here. Our fundamental mission is to support and enhance the doctor-patient relationship, not to replace it.
We maintain strict quality controls on all our partner retailers, so that you always get standard quality products.
100% secure and trusted payment protection
We have a new and dynamic return window policy for medicines and healthcare items. Refer FAQs section for more details.
